Compare Analog Devices, Inc. (ADI) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs DexCom, Inc. — how do they compare? Analog Devices, Inc. trades at $384.42 (market cap $187.67B), while DexCom, Inc. trades at $90.23 (market cap $33.79B). The key difference: Analog Devices, Inc. is far larger — about 5.6× DexCom, Inc.'s market cap, and Analog Devices, Inc. pays a 1.14% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| ADI | DXCM | |
|---|---|---|
Market Cap | $187.67B | $33.79B |
Sector | Technology | Health |
52-Week High | $445.48 | $89.53 |
52-Week Low | $225.20 | $54.84 |
Enterprise Value | $192.92B | $33.24B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.29, up 0.1% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q1 2026 EPS of $3.09, exceeding expectations, and maintains strong profitability with a 26.01% net income margin. A dividend of $1.10 per share is scheduled for payment on June 16, 2026, reflecting cash flow stability.
ADI presents a favorable investment case with analyst consensus strongly bullish (79.63% buy ratings) and a price target of $472.29, implying significant upside. Risks include elevated valuation multiples (P/E of 57.34) and semiconductor cycle volatility, but robust fundamentals and AI-driven demand support long-term growth prospects.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
